Human Immunodeficiency Virus I Infection
13
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
90.0%
+3.5% vs benchmark
15%
2 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
ICVAX as a HIV Therapeutic DNA Vaccine
Managing Hypertension Among People Living With HIV
A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US
A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses
MMF for HIV Reservoir Reduction
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed
Optimization of Darunavir Therapy and Dosage Recommendations
An Automated, Tailored Information Application for Medication Health Literacy
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes